MaggioreUAbramowiczDCrespoM, et al.How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrol Dial Transplant. 2020;35(6):899–904. doi:10.1093/ndt/gfaa130
2.
LaurenceJMulveyJJSeshadriM, et al.Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555. doi:10.1016/j.clim.2020.108555
3.
MastellosDCPires da SilvaBGPFonsecaBAL, et al.Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. doi:10.1016/j.clim.2020.108598
4.
TrimarchiHGianserraRLampoMMonkowskiMLodoloJ. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. Clin Kidney J. 2020;13(5):739–741. doi:10.1093/ckj/sfaa166
5.
AratenDJBelmontHMSchaefer-CutilloJIyengarAMattooAReddyR. Mild clinical course of COVID-19 in 3 patients receiving therapeutic monoclonal antibodies targeting c5 complement for hematologic disorders. Am J Case Rep. 2020;21:e927418. doi:10.12659/AJCR.927418
